Viewing nowCombinationRivaroxaban 2/80 mg Tablets
Pitavastatin Calcium Hydrate 2mg · Valsartan 80mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corp.

MFDS item code 201500967 · Approved 2015.02.25 · Insurance code 644913910
Treatment of dyslipidemia, hypertension, and heart failure, reduction of the risk of death after myocardial infarction
This medication is only used for patients who require the combined administration of pitavastatin calcium and valsartan. Pitavastatin calcium helps to lower total cholesterol, LDL cholesterol, apolipoprotein B, and triglyceride levels, and increase HDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia, in conjunction with dietary therapy. Valsartan is used for the treatment of essential hypertension, and is effective in patients with heart failure who are intolerant to ACE inhibitors. Additionally, it reduces the risk of death after myocardial infarction in stable patients with heart left ventricle dysfunction. Therefore, this medication is used to improve the management of cardiovascular diseases such as hypertension, heart failure, and dyslipidemia.
This drug should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, pitavastatin calcium and valsartan. This drug should be taken once daily after breakfast. Since aminotransferase levels may increase during treatment with this drug, liver function tests should be performed before and during treatment. Liver function tests should be performed at least once within 12 weeks of starting treatment and regularly thereafter (e.g., once every 6 months). Exercise particular caution in patients with elevated serum aminotransferase levels, and perform liver function tests promptly and frequently. Pitavastatin calcium Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug. The usual initial dose for adults is 1~2 milligrams of pitavastatin calcium taken once daily. If the reduction in LDL cholesterol is insufficient, the dose may be increased to a maximum of 4 milligrams daily. Depending on LDL cholesterol levels, the treatment goal, and the patient's response, the dose should be adjusted as appropriate at intervals of 4 weeks or longer. The therapeutic effect of this drug is maintained with continued administration. Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the drug be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The antihypertensive effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Initiate treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this drug once daily; the dose should not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this drug orally twice daily, which may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this drug twice daily. The dose may then be increased over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this drug to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. For patients taking pitavastatin calcium and valsartan concomitantly, they may switch to this drug (a combination product containing the same amount of each active ingredient) for convenience.
6) Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus and newborn especially during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used by individuals allergic to this drug or its components, pregnant or breastfeeding women, patients with severe liver impairment or liver disease, patients with a history of hereditary angioedema, or patients with severe kidney impairment. Elderly patients, patients with high potassium levels, liver impairment, heart disease, or kidney impairment should use this medication with special caution. This medication may cause muscle-related adverse reactions such as myalgia and muscle weakness, as well as liver dysfunction, blood abnormalities, and allergic reactions; therefore, if symptoms appear, consult a physician immediately. Since this medication lowers blood pressure, hypotension may occur, and there is also a risk of dizziness or fainting, so caution is needed when driving or operating machinery. Interactions may occur when this medication is combined with others, so it is essential to inform the healthcare provider of any medications being taken. Pregnant or breastfeeding women are advised not to take this medication, but if it is necessary, they should consult a specialist for a cautious decision. The safety and effectiveness in pediatric patients have not been established; therefore, it is generally recommended not to use it in this population. In cases of an overdose, severe hypotension, altered consciousness, shock, etc., emergency care should be sought immediately. This medication should be kept out of the reach of children and should not be transferred to other containers for safety.
Headache, indigestion, nausea, elevated serum AST, chest discomfort, increased sweating, dizziness, abdominal pain, rash, lethargy, paralysis, itching, elevated γ-GT, elevated plasma creatine phosphokinase levels, elevated serum ALT, elevated serum AST, rhabdomyolysis, myopathy, liver dysfunction, jaundice, thrombocytopenia, urticaria, erythema, angioedema, elevated bilirubin, increased cholinesterase, rigidity, drowsiness, insomnia, heaviness in the head, thirst, abdominal distension, constipation, stomatitis, vomiting, anorexia, glossitis, thrombocytopenia, granulocytopenia, leukopenia, eosinophilia, leukocytosis, elevated globulin, anemia, increased urinary frequency, elevated BUN, elevated serum creatinine, decreased aldosterone, elevated aldosterone, increased adrenocorticotropic hormone, elevated cortisol, decreased testosterone, muscle cramps, elevated CPK, myalgia, weakness, palpitations, fatigue, skin pain, burning sensation, arthralgia, edema, blurred vision, photophobia, hearing loss, hematuria, elevated uric acid levels, increased serum potassium and phosphorus, taste disturbance, lethargy, positive antinuclear antibody, sleep disturbances, memory loss, depression, interstitial lung disease, sexual dysfunction, diabetes, immune-mediated necrotizing myopathy, severe muscle weakness, ocular myasthenia, hypopigmented anemia, facial edema, arm swelling, hypersensitivity, skin paresthesia, insomnia, loss of appetite, increased blood pressure, weakness, thirst, thrombocytopenia, increased blood creatinine, increased BUN, angioedema, renal impairment, hyperkalemia, shock, syncope, loss of consciousness, vesicular dermatitis, intestinal vascular edema, hepatitis, arrhythmia, interstitial pneumonia, hypoglycemia, vasculitis, agranulocytosis, leukopenia, thrombocytopenia, increased tension, reduced motor function, confusion, chest pain, rash, myalgia
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container that prevents light exposure, and it is safe to store between temperatures of 1 to 30 degrees Celsius at room temperature. Therefore, it is important to avoid direct sunlight and not to place it in excessively hot or cold locations.
Pink round film-coated tablets
30 tablets (6 tablets/PTP x 5)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationPitavastatin Calcium Hydrate 2mg · Valsartan 80mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corp.
CombinationPitavastatin Calcium Hydrate 4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corp.
CombinationPitavastatin Calcium Hydrate 4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Co., Ltd.
CombinationPitavastatin Calcium Hydrate 2mg · Valsartan 160mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corp.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.